Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - Between options

Journal of Contemporary Brachytherapy

Volumn 5, Issue 1, 2013, Pages 33-41

  Skowronek, Janusz ^a,b  

^a GREATER POLAND CANCER CENTER   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Brachytherapy; HDR; LDR; Prostate cancer; Seeds

Indexed keywords

COBALT 60; IRIDIUM 192;

BRACHYTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL RECTAL EXAMINATION; DOSIMETRY; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; GOLD STANDARD; HOSPITALIZATION; HUMAN; LONG TERM CARE; MONOTHERAPY; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGANS AT RISK; PATIENT SELECTION; PROSTATE CANCER; PROSTATE VOLUME; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION SAFETY; RADIOISOTOPE THERAPY; RESIDUAL URINE; REVIEW; RISK FACTOR; SURVIVAL RATE; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION; TREATMENT PLANNING; URINE FLOW RATE;

EID: 84876861867     PISSN: 1689832X     EISSN: None     Source Type: Journal    
DOI: 10.5114/jcb.2013.34342     Document Type: Review

References (40)

1. Nag S, Beyer D, Friedland J et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44: 789-799. (Pubitemid 29284127)
2. Porter AT, Blasko JC, Grimm PD et al. Brachytherapy for Prostate Cancer. Cancer J Clin 1995; 45: 165-178.
3. Garbaulet A, Potter R, Mazeron JJ et al. The GEC ESTRO Handbook of Brachytherapy. Brussels 2002; chapter 20, pp. 473-480.
4. Ash D, Flynn A, Battermann J, de Reijke T et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radioth Oncol 2000; 57: 315-321.
5. Thompson I, Thrasher JB, Aus G et al. Guidelines for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 2106-2131. (Pubitemid 46726449)
6. Horwich A, Parker C, Bangma C et al. ESMO Guidelines Working Group. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; Suppl 5: 129-133.
7. Skowronek J, Kanikowski M, Zwierzchowski G et al. Brachyterapia LDR w leczeniu raka gruczołu krokowego. Wspolczesna Onkol 2009; 13: 316-329 [In Polish].
8. Mohler J, Bahnson RR, Boston B et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8: 162-200.
9. Grimm P, Billiet I, Bostwick D et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012; 109 Suppl 1: 22-29.
10. Crook JM, Gomez-Iturriaga A, Wallace K et al. Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol 2011; 29: 362-368.
11. Ferrer M, Suarez JF, Guedea F et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72: 421-432.
12. Sylvester JE, Grimm PD, Wong J et al. Fifteen-Year Biochemical Relapse-Free Survival, Cause-Specific Survival, and Overall Survival following I-125 Prostate Brachytherapy in Clinically Localized Prostate Cancer: Seattle Experience. Int J Radiat Oncol Biol Phys 2011; 81: 376-381.
13. Polascik TJ, Pound CR, DeWeese TL et al. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. Urology 1998; 51: 884-889; discussion 889-90.
14. Machtens S, Baumann R, Hagemann J et al. Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World J Urol 2006; 24: 289-295. (Pubitemid 44138184)
15. Kovacs G, Potter R, Tillmann L et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localized prostate cancer. Radiother Oncol 2005; 74: 137-148. (Pubitemid 40331870)
16. Burchardt W, Skowronek J, Łyczek J. Samodzielna brachyterapia HDR raka gruczołu krokowego - alternatywa we wczesnym stopniu zaawansowania. Przegl Urol 2012; 4: 33-38 [in Polish].
17. Chicheł A, Kanikowski M, Skowronek J et al. Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high-dose-rate bra chytherapy (HDR-BT) as a boost. J Contemp Brachytherapy 2009; 1: 11-17.
18. Seppenwoolde Y, Kolkman-Deurloo I-K, Sipkema D et al. HDR prostate monotherapy - dosimetric effects of implant deformation due to posture change between TRUS- and CT-imaging. Radiother Oncol 2008; 86: 114-119.
19. Martin T, Baltas D, Kurek R et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol 2004; 180: 225-232. (Pubitemid 38461547)
20. Galalae RM, Kovacs G, Schultze J et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2002; 52: 81-90. (Pubitemid 34044108)
21. Kanikowski M, Skowronek J, Milecki P et al. Brachyterapia HDR raka gruczołu krokowego. Urologia Polska 2007; 2: 5-11 [in Polish].
22. Chicheł A, Kanikowski M, Skowronek J et al. Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high-dose-rate brachytherapy (HDR-BT) as a boost. J Contemp Brachytherapy 2009; 1: 11-17.
23. Martinez AA, Gustafson G, Gonzalez J et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 316-327. (Pubitemid 34522097)
24. Demanes DJ, Rodriguez RR, Altieri GA. High dose rate prostate brachytherapy: the California Endocurietherapy (CET) Method. Radiother Oncol 2000; 57: 289-296.
25. Demanes DJ, Rodriguez RR, Schour L et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California Endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005; 61: 1306-1316. (Pubitemid 40470411)
26. Hsu I-C, Yamada Y, Vigneault E et al. American Brachytherapy Society Prostate High-Dose Rate Task Group." Retrieved 15-03-2010, 2010, from http://www.americanbrachytherapy.org/guidelines/index.cfm.
27. Demanes DJ, Martinez AA, Ghilezan M et al. High-Dose-Rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011; 81: 1286-1292.
28. Martinez AA, Demanes J, Vargas C et al. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 2010; 33: 481-488.
29. Rogers L, Rogers LI. Extended follow up of high-dose-rate brachytherapy as monotherapy for intermediate- risk prostate cancer. Brachytherapy 2010; 9 (Suppl. 1): S55-S56.
30. Yoshioka Y, Konishi K, Oh RJ et al. High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol 2006; 80: 62-68. (Pubitemid 44226435)
31. Yoshioka Y, Konishi K, Sumida I et al. Monotherapeutic High-Dose-Rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys 2011; 80: 469-475.
32. Martinez AA, Pataki I, Edmundson G et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 2001; 49: 61-69. (Pubitemid 32041277)
33. Merrick GS, Zelefsky M, Sylvester K et al. American Brachytherapy Society Prostate Low-Dose Rate Task Group. http://www.americanbrachytherapy.org/ guidelines/prostate-low-doseratetaskgroup.pdf
34. Merrick GS, Butler WM, Galbreath RW et al. Biochemical outcome for hormone-naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy. Urology 2002; 60: 98-103. (Pubitemid 34722955)
35. Wallner K, Lee H, Wasserman S et al. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997; 37: 565-569. (Pubitemid 27175311)
36. Lee WR. The role of androgen deprivation therapy combined with prostate brachytherapy. Urology 2002; 60 (3 Suppl 1): 39-44; discussion 44.
37. Pujades MaC, Camacho C, Perez-Calatayud J et al. The use of nomograms in LDR-HDR prostate brachytherapy. J Contemp Brachytherapy 2011; 3: 121-124.
38. King CR. LDR vs HDR brachytherapy for localized prostate cancer- the view from radiobiological models. Brachytherapy 2002; 1: 219-228.
39. Leibel SA, Phillips TL. Textbook of Radiation Oncology, Second Edition 2004, Chapter 45, 988-1000.
40. Grills IS, Martinez AA, Hollander M et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004; 171: 1098-1104. (Pubitemid 38327535)